Cancer
|
Complete case
|
Weighted
|
---|
Odds Ratio (95% CI)
|
p-value
|
Odds Ratio (95% CI)
|
p-value
|
---|
ADC
|
4.50 (4.35–4.65)
|
< 0.0001
|
3.46 (3.33–3.59)
|
< 0.0001
|
Kaposi
|
134 (111–161)
|
< 0.0001
|
98.8 (80.9–120)
|
< 0.0001
|
Cervix
|
1.70 (1.63–1.77)
|
< 0.0001
|
1.68 (1.60–1.76)
|
< 0.0001
|
NHL
|
2.73 (2.56–2.91)
|
< 0.0001
|
2.89 (2.71–3.08)
|
< 0.0001
|
Burkitt’s lymphoma
|
6.48 (5.21–8.07)
|
< 0.0001
|
7.83 (6.38–9.62)
|
< 0.0001
|
Non-Hodgkins NOS
|
4.26 (3.4–5.34)
|
< 0.0001
|
4.85 (3.88–6.07)
|
< 0.0001
|
DLBCL
|
2.93 (2.67–3.22)
|
< 0.0001
|
3.27 (3.00–3.59)
|
< 0.0001
|
DILBCL
|
12.1 (9.02–16.3)
|
< 0.0001
|
12.0 (8.91–16.1)
|
< 0.0001
|
Follicular
|
0.65 (0.49–0.87)
|
0.004
|
0.73 (0.55–0.98)
|
0.038
|
NADC
|
0.26 (0.25–0.26)
|
< 0.0001
|
0.36 (0.35–0.38)
|
< 0.0001
|
Virus-related NADC
|
0.75 (0.71–0.78)
|
< 0.0001
|
0.77 (0.73–0.82)
|
< 0.0001
|
Anus
|
1.63 (1.33–2.00)
|
< 0.0001
|
1.61 (1.30–1.99)
|
< 0.0001
|
Hodgkin’s lymphoma
|
1.22 (1.09–1.37)
|
< 0.0001
|
1.43 (1.27–1.61)
|
< 0.0001
|
Liver
|
0.45 (0.39–0.53)
|
< 0.0001
|
0.51 (0.42–0.61)
|
< 0.0001
|
Vulva
|
1.94 (1.67–2.25)
|
< 0.0001
|
1.82 (1.58–2.10)
|
< 0.0001
|
Vagina
|
0.83 (0.67–1.03)
|
0.09
|
0.88 (0.70–1.11)
|
0.29
|
Penis
|
2.35 (1.85–2.99)
|
< 0.0001
|
2.06 (1.63–2.61)
|
< 0.0001
|
Lip, oral cavity and Pharynx (C00-C14)
|
0.55 (0.50–0.59)
|
< 0.0001
|
0.67 (0.61–0.73)
|
< 0.0001
|
Gum
|
0.74 (0.41–1.36)
|
0.34
|
0.90 (0.46–1.76)
|
0.76
|
Lip
|
2.72 (1.71–4.32)
|
< 0.0001
|
3.47 (1.95–6.16)
|
< 0.0001
|
Mouth
|
0.56 (0.49–0.66)
|
< 0.0001
|
0.63 (0.53–0.75)
|
< 0.0001
|
Naso-oropharynx
|
0.48 (0.42–0.56)
|
< 0.0001
|
0.57 (0.48–0.68)
|
< 0.0001
|
Salivary gland
|
0.65 (0.51–0.82)
|
< 0.0001
|
0.71 (0.54–0.93)
|
0.01
|
Tongue
|
0.51 (0.43–0.60)
|
< 0.0001
|
0.57 (0.47–0.70)
|
< 0.0001
|
Virus-unrelated NADC
|
0.30 (0.29–0.31)
|
< 0.0001
|
0.43 (0.42–0.45)
|
< 0.0001
|
BCC
|
1.27 (1.08–1.49)
|
< 0.0001
|
1.39 (1.17–1.67)
|
< 0.0001
|
Bladder
|
0.74 (0.61–0.89)
|
< 0.0001
|
0.86 (0.69–1.08)
|
0.2
|
Bone
|
0.32 (0.26–0.40)
|
< 0.0001
|
0.41 (0.30–0.54)
|
< 0.0001
|
Brain
|
0.27 (0.22–0.34)
|
< 0.0001
|
0.34 (0.26–0.43)
|
< 0.0001
|
Colorectal
|
0.43 (0.38–0.47)
|
< 0.0001
|
0.55 (0.48–0.62)
|
< 0.0001
|
Eye
|
5.9 (5.11–6.82)
|
< 0.0001
|
7.73 (6.60–9.05)
|
< 0.0001
|
Conjunctiva
|
21.5 (16.3–28.4)
|
< 0.0001
|
20.8 (15.2–28.5)
|
< 0.0001
|
Haematology
|
0.49 (0.37–0.65)
|
< 0.0001
|
0.58 (0.43–0.80)
|
< 0.0001
|
Kidney
|
0.18 (0.15–0.21)
|
< 0.0001
|
0.23 (0.19–0.29)
|
< 0.0001
|
Larynx
|
0.56 (0.49–0.64)
|
< 0.0001
|
0.62 (0.53–0.72)
|
< 0.0001
|
Leukaemia
|
0.25 (0.23–0.28)
|
< 0.0001
|
0.33 (0.30–0.37)
|
< 0.0001
|
Lung
|
0.52 (0.48–0.57)
|
< 0.0001
|
0.62 (0.56–0.68)
|
< 0.0001
|
Melanoma
|
0.77 (0.63–0.93)
|
0.01
|
0.95 (0.76–1.20)
|
0.69
|
Mesothelioma
|
0.50 (0.34–0.75)
|
< 0.0001
|
0.51 (0.32–0.80)
|
< 0.0001
|
Myeloma
|
0.61 (0.52–0.71)
|
< 0.0001
|
0.75 (0.63–0.89)
|
< 0.0001
|
Oesophagus
|
0.57 (0.52–0.64)
|
< 0.0001
|
0.58 (0.52–0.66)
|
< 0.0001
|
Pancreas
|
0.43 (0.33–0.58)
|
< 0.0001
|
0.60 (0.42–0.84)
|
< 0.0001
|
SCC Skin
|
1.83 (1.64–2.04)
|
< 0.0001
|
1.88 (1.67–2.11)
|
< 0.0001
|
Skin
|
0.95 (0.77–1.16)
|
0.6
|
1.11 (0.87–1.41)
|
0.41
|
Small intestines
|
0.33 (0.23–0.48)
|
< 0.0001
|
0.35 (0.24–0.53)
|
< 0.0001
|
Stomach
|
0.43 (0.37–0.49)
|
< 0.0001
|
0.58 (0.49–0.70)
|
< 0.0001
|
Thyroid
|
0.75 (0.59–0.95)
|
0.02
|
1.01 (0.74–1.37)
|
0.97
|
Uterus
|
0.38 (0.34–0.43)
|
< 0.0001
|
0.44 (0.39–0.50)
|
< 0.0001
|
Breast
|
0.43 (0.41–0.45)
|
< 0.0001
|
0.50 (0.47–0.53)
|
< 0.0001
|
Placenta
|
0.85 (0.58–1.24)
|
0.39
|
1.05 (0.70–1.56)
|
0.83
|
Prostate
|
0.85 (0.76–0.95)
|
< 0.0001
|
0.95 (0.84–1.08)
|
0.46
|
Testis
|
0.37 (0.26–0.53)
|
< 0.0001
|
0.48 (0.32–0.74)
|
< 0.0001
|
Poorly specified histology at any site
|
0.82 (0.77–0.88)
|
< 0.0001
|
0.95 (0.88–1.03)
|
0.2
|
- OR Odds ratios determined using logistic regression models adjusting for age, gender, race, province and year of cancer diagnosis, NHL non-Hodgkin’s lymphoma, DLBCL Diffuse large B-cell lymphoma, DILBCL Diffuse Immunoblastic Large B-cell lymphoma, NOS Not Otherwise Specified, BCC Basal cell carcinoma, ADC AIDS defining cancer, NADC non-AIDS defining cancer, SCC skin squamous cell carcinoma of the skin, Virus-related NADCs liver cancer (hepatitis viruses), penis, vulva, vagina, anal, lip, mouth, gum, salivary gland and tonsil (Human Papilloma Virus (HPV) associated malignancies other than cervix), and Hodgkin’s lymphoma and nasopharyngeal cancer (Epstein Barr Virus (EBV)). The weighted analysis included inverse probability weights estimated from known HIV status age, gender, cancer diagnosis and cancer diagnosis year